LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Net Income
-$41.7m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Net Income
-$17.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Net Income
-€23.9m
CAGR 3-Years
25%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Net Income
-$239.5m
CAGR 3-Years
N/A
CAGR 5-Years
-18%
CAGR 10-Years
-18%
argenx SE
XBRU:ARGX
Net Income
-$358.1m
CAGR 3-Years
-31%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Net Income
-$244.6m
CAGR 3-Years
-45%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Net Income?
Net Income
-41.7m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Net Income amounts to -41.7m USD.

What is LAVA Therapeutics NV's Net Income growth rate?
Net Income CAGR 3Y
-39%

Over the last year, the Net Income growth was -32%. The average annual Net Income growth rates for LAVA Therapeutics NV have been -39% over the past three years .

Back to Top